141 related articles for article (PubMed ID: 29274720)
1. Clinical significance of defining borderline resectable pancreatic cancer.
Kang MJ; Jang JY; Kwon W; Kim SW
Pancreatology; 2018 Mar; 18(2):139-145. PubMed ID: 29274720
[TBL] [Abstract][Full Text] [Related]
2. Borderline resectable pancreatic cancer: More than an anatomical concept.
Petrelli F; Inno A; Barni S; Ghidini A; Labianca R; Falconi M; Reni M; Cascinu S;
Dig Liver Dis; 2017 Feb; 49(2):223-226. PubMed ID: 27931968
[TBL] [Abstract][Full Text] [Related]
3. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
di Sebastiano P; Grottola T; di Mola FF
Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
[TBL] [Abstract][Full Text] [Related]
4. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer.
Barreto SG; Loveday B; Windsor JA; Pandanaboyana S
ANZ J Surg; 2019 May; 89(5):481-487. PubMed ID: 30117669
[TBL] [Abstract][Full Text] [Related]
5. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
[TBL] [Abstract][Full Text] [Related]
6. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.
Yasuta S; Kobayashi T; Aizawa H; Takahashi S; Ikeda M; Konishi M; Kojima M; Kuno H; Uesaka K; Morinaga S; Miyamoto A; Toyama H; Takakura N; Sugimachi K; Takayama W
BMC Cancer; 2020 Dec; 20(1):1184. PubMed ID: 33267820
[TBL] [Abstract][Full Text] [Related]
7. "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer.
Lombardi P; Silvestri S; Marino D; Santarelli M; Campra D; De Paolis P; Aglietta M; Leone F;
Crit Rev Oncol Hematol; 2019 Jan; 133():17-24. PubMed ID: 30661653
[TBL] [Abstract][Full Text] [Related]
8. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
Wang G; Zhou D
Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
[TBL] [Abstract][Full Text] [Related]
9. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
[TBL] [Abstract][Full Text] [Related]
10. How to treat borderline resectable pancreatic cancer: current challenges and future directions.
Takahashi S
Jpn J Clin Oncol; 2018 Mar; 48(3):205-213. PubMed ID: 29340601
[TBL] [Abstract][Full Text] [Related]
11. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
Kang CM; Hwang HK; Choi SH; Lee WJ
Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
[TBL] [Abstract][Full Text] [Related]
12. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
13. [Resectability of pancreatic cancer: New criteria].
D'Haese JG; Werner J
Radiologe; 2016 Apr; 56(4):318-24. PubMed ID: 26993121
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
Schwarz L; Katz MH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
[TBL] [Abstract][Full Text] [Related]
15. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
[TBL] [Abstract][Full Text] [Related]
16. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.
Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
Ann Oncol; 2017 Sep; 28(9):2067-2076. PubMed ID: 28407088
[TBL] [Abstract][Full Text] [Related]
17. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
Mortensen MB
Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
[TBL] [Abstract][Full Text] [Related]
18. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer.
He J; Schulick RD; Del Chiaro M
Ann Surg Oncol; 2021 Mar; 28(3):1514-1520. PubMed ID: 33415556
[TBL] [Abstract][Full Text] [Related]
19. Preoperative CT staging of borderline pancreatic cancer patients after neoadjuvant treatment: accuracy in the prediction of vascular invasion and resectability.
Ahmed SA; Mourad AF; Hassan RA; Ibrahim MAE; Soliman A; Aboeleuon E; Elbadee OMA; Hetta HF; Jabir MA
Abdom Radiol (NY); 2021 Jan; 46(1):280-289. PubMed ID: 32488556
[TBL] [Abstract][Full Text] [Related]
20. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
